SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors weigh potential bipartisan legislation aimed at restricting sports betting contracts on unregulated prediction markets, a move that could shift market share toward licensed operators. Meanwhile, social media sentiment remains highly divided, with retail investors expressing intense frustration over recent price declines and insider selling while others monitor how potential regulatory changes might impact the competitive landscape for sportsbooks.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing heightened investor attention following the upcoming departure of a key FDA official, which market participants view as a potential catalyst for a more predictable regulatory environment for rare disease gene therapies. The community remains heavily focused on the company's strong revenue base and upcoming clinical data readouts for its siRNA pipeline, with many investors actively debating the stock's valuation versus its growth potential.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over the company's heavy AI capital expenditures, the uncertain ROI of OpenAI, and a broader rotation away from software stocks. The community is deeply divided, with many debating whether the current price represents a generational buying opportunity for a fundamental giant or if the stock is broken due to perceived leadership failures and a lack of clear AI monetization.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund is experiencing extreme volatility and massive upside momentum as retail investors chase exposure to high-profile private AI and space firms like SpaceX and Anthropic. While the community is debating the disconnect between the fund's net asset value and its current trading premium, bullish sentiment remains fueled by the limited float due to share lockups and anticipation of upcoming IPOs.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Investors are flocking to Orcasm, a new crypto project, driven by its low supply compared to similar marine-themed meme coins and intense social media speculation. While some participants are betting on significant growth and the shift toward ocean-based narratives, others warn of volatility and caution against potential risks associated with these types of assets.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility following a regulatory setback, where the FDA issued a complete response letter regarding its drug candidate relacorilant for Cushing's syndrome due to requests for additional efficacy data. While the stock has faced intense selling pressure and scrutiny over the regulatory delay and ongoing patent litigation, the community is actively debating whether the sell-off is an overreaction given the company's established, profitable Korlym franchise and the upcoming pivotal data readouts for its oncology pipeline.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention as investors position themselves for a potential SpaceX IPO, with the stock viewed by many as a unique vehicle to gain exposure to high-growth private tech giants like SpaceX, OpenAI, and Anthropic. Community discussion remains polarized, however, as some traders highlight the stock's potential for high volatility and a potential short squeeze due to its low float, while others express caution regarding its valuation relative to its Net Asset Value (NAV) and the risks of paying a premium for closed-end fund holdings.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is trending as investors react to the companys recent reverse stock split, sparking intense debate over whether the move signals a structural turnaround or a continuation of the stock's long-term decline. The community is sharply divided, with some betting on a potential short squeeze due to a smaller float, while others express frustration over management's lack of communication and the stock's history of value destruction.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently the center of intense market discussion following a strategic shift to sell its own in-house AGI CPU chips for data centers, which management expects will generate billions in annual revenue by 2031. Investors and analysts are actively debating the company's valuation and the potential for a massive rerating, as the move pivots Arm from a traditional IP licensing model to a direct silicon competitor in the AI-driven data center market.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is facing intense volatility as investors debate the merit of a critical short report alleging aggressive accounting practices, while the company maintains its long-term growth narrative. The community remains deeply divided, with many long-term shareholders aggressively buying the dip on conviction that the allegations are unfounded, while others remain cautious due to management's muted initial response and the stock's significant price decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics

TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.

Myriad Genetics (NASDAQ:MYGN) CEO Buys 40,000 Shares

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) CEO Samraat Raha bought 40,000 shares of the stock in a transaction on Monday, March 9th. The shares were bought at an average price of $5.00 per...

Myriad Genetics (NASDAQ:MYGN) CEO Purchases $200,000.00 in Stock

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) CEO Samraat Raha bought 40,000 shares of Myriad Genetics stock in a transaction on Monday, March 9th. The shares were purchased at an average...

Royce & Associates LP Makes New $4.84 Million Investment in Myriad Genetics, Inc. $MYGN

Royce & Associates LP acquired a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and...

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have earned a consensus rating of "Hold" from the thirteen brokerages that are currently covering the company, Marketbeat.com reports...

S. Louise Phanstiel Buys 48,000 Shares of Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director S. Louise Phanstiel bought 48,000 shares of the company's stock in a transaction dated Friday, February 27th. The shares were purchased...

Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research

Zacks Research raised Myriad Genetics from a "strong sell" rating to a "hold" rating in a research report on Thursday...

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Current Price	$4.75
Prev Close	$4.61
Open	$4.70
Dividend Yield	0.00%
50-Day Moving Average	$5.14
Beta	1.18
Avg. Volume	1.49M
PE Ratio	-1.17

52-Week High	$9.88
52-Week Low	$3.76
Market Capitalization	$431.07M
EPS (Annual)	-$3.95
Price to Book	1.17
Revenue Per Employee	$305,370.37

MYGN
Myriad Genetics, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MYGN News

MYGNMyriad Genetics, Inc.